Genomics in Precision Oncology Xchange
March 30, 2022
Welcome to hubXchange’s West Coast Hybrid Genomics in Precision Oncology 2022, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in genomics-led oncology precision medicine strategies.
Discussion topics will cover Cancer Genomics, Translational Bioinformatics, Data Quality & Access and Genomics Informed Clinical Decisions.
Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking with your peers.
Please note this is a HYBRID meeting. Participants can join in-person and virtually. All COVID safety protocols will be adhered to.
Venue Details – DoubleTree by Hilton San Francisco Airport Hotel, 835 Airport Boulevard, Burlingame CA 94010-9949
Opening Address & Keynote: Connecting Biomarker Development with Disease Detection and Monitoring
- Better characterizing disease biology in order to more fully understand tumor heterogeneity
- Enabling more sophisticated diagnostic tests to address therapy-induced tumor evolution
- Improving outcomes with ongoing disease molecular assessment and treatment management based upon molecular endpoints
President & CEO, Stilla Technologies
Philippe is an executive life sciences leader with over 25 years’ experience gained through leadership roles at global organizations serving drug discovery and development organizations and with his strong biomarker landscape knowledge has a proven track record of influencing both translational and clinical programs.
Connecting cancer genomics with environmental stress adaptation: Considerations for drug discovery
- Tumor targeted therapies in genetically defined patient populations have revolutionized cancer treatment paradigms. However, innate or acquired therapy resistance cannot be completely explained by genetic hypotheses.
- It is increasingly recognized that environmental pressures promote tumor dependencies that may or may not be genetically driven.
- This discussion will focus on our emerging understanding of tumor genetic lesions and their cross-talk with environmental stressors.
- Can these learnings inform on the next generation of cancer drugs or on novel therapeutic combinations?
Senior Director, Head of Translational Sciences, Pioneering Medicines
Charles is a Senior Director and Head of Translational Sciences at Pioneering Medicines. Prior to this, he was Senior Principal Scientist at Bristol-Myers Squibb, leading drug discovery programs targeting the interface between tumor-intrinsic biology and the tumor microenvironment. Charles originally trained as an immunologist, completing his PhD in immune cell biology at the MRC National Institute for Medical Research (London, UK) and postdoctoral training in inflammation at Emory University. He previously led a small molecule immuno-oncology group at AstraZeneca (Cambridge, UK), where his team discovered a clinical candidate antisense oligonucleotide targeting FOXP3. Charles also has a longstanding interest to understand the immunomodulatory functions of the PI3K/MTOR signaling pathway in cancer and inflammation.
Beyond genomics for oncology biomarkers: opportunities and challenges of multi-omics approaches
- How multiple mutations lead to the same phenotypes and how can we account for them?
- Can gene expression uncover cellular states related to drug sensitivity?
- What are the challenges to get non-genomic based tests in the clinic?
- Can other omics such as methylation and histone marks be used for translational research?
Senior Bioinformatics Scientist, Genentech
As a computational biologist in oncology research at Genentech, Marc Hafner works towards characterizing new therapeutic targets, supporting the development of new drugs, and identifying the patient populations that would most benefit from these drugs. For his personal research, Marc is leveraging pre-clinical and clinical data including real-world data to understand drug mechanisms of resistance. Marc is also leading the implementation of a drug response software suite that leverage the GR method he developed during his postdoc.
3:45 – 4:45pm
New genomics technologies for cancer target identification and characterization – opportunities and challenges
- Which new technologies are on the horizon for target identification and characterization?
- Are novel technologies in the spatial transcriptomics (Stereo-seq, Slide-seq) and CRISPR single-cell sequencing (TAP-seq) field advanced enough to provide a benefit for target identification and characterization?
- How do the cancer genomics field and target identification benefit from spatial transcriptomics approaches (or other novel technologies)?
- Evaluating gene perturbation effects on single-cell level – challenges and benefits
Senior Scientist, Bioinformatics, Merck
Milena Hornburg is a Senior Scientist in the Genome and Biomarker Science Department at Merck. As part of the oncology computational biology group, her work focuses on novel target identification and characterization working with large NGS datasets spanning from traditional RNA-seq to novel spatial transcriptomics and single-cell CRISPR-seq technology data. Prior to Merck, Milena completed her postdoc at Genentech in the Bioinformatics and Computational Biology department where she collaborated with Oncology Biomarker Development on the investigation of the tumor microenvironment and its’ association with tumor immune infiltration (Hornburg et al. Cancer Cell 2021, Desbois et al. Nature Medicine 2020).